Ad Hoc

Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to…

Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN…

Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating…

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing…

Ad hoc announcement pursuant to Art. 53 LR Mukul Mehta, currently Head of Business Planning and Analysis (BPA),…

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…

Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +7% (cc1, +8% USD) and core…

Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for…

Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in…

Ad-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr Der Nettoumsatz wuchs um +8% (kWk1, +8% USD), das operative Kernergebnis1 verbesserte sich…

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +8% (cc1, +8% USD) with…

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer